Abstract
BACE1, the aspartate protease that generates amyloid-β peptide (Aβ) in the brain of AD (Alzheimer’s disease) patients, has emerged as a pharmaceutically relevant target. Here, a fragment-based in silico approach has been adopted to design novel compounds with increased ligand efficiency for BACE1, before screening for brain permeability and toxicity. Fragments docked to the active site of BACE1 and sorted into two groups using binding energy cut-off, were joined to create novel ligands with binding energy lying in the range between -11.36 kcal/mol and -8.56 kcal/mol. Interestingly, QIN, a known inhibitor of BACE1 with an IC50 of 11nM, when docked to BACE1, shows a binding energy (-9.43 kcal/mol) lying within the range of the novel ligand-BACE1 complexes. The present strategy thus enabled the design of four novel inhibitors of BACE1 with favourable binding energy, brain permeability and no toxicity that might show promise as leads in future.
Keywords: BACE1, inhibitors, fragment, binding energy, design.
Graphical Abstract
Central Nervous System Agents in Medicinal Chemistry
Title:Fragment-based Designing for the Generation of Novel Leads Against BACE1
Volume: 15 Issue: 1
Author(s): Sucharita Das, Sandipan Chakraborty and Soumalee Basu
Affiliation:
Keywords: BACE1, inhibitors, fragment, binding energy, design.
Abstract: BACE1, the aspartate protease that generates amyloid-β peptide (Aβ) in the brain of AD (Alzheimer’s disease) patients, has emerged as a pharmaceutically relevant target. Here, a fragment-based in silico approach has been adopted to design novel compounds with increased ligand efficiency for BACE1, before screening for brain permeability and toxicity. Fragments docked to the active site of BACE1 and sorted into two groups using binding energy cut-off, were joined to create novel ligands with binding energy lying in the range between -11.36 kcal/mol and -8.56 kcal/mol. Interestingly, QIN, a known inhibitor of BACE1 with an IC50 of 11nM, when docked to BACE1, shows a binding energy (-9.43 kcal/mol) lying within the range of the novel ligand-BACE1 complexes. The present strategy thus enabled the design of four novel inhibitors of BACE1 with favourable binding energy, brain permeability and no toxicity that might show promise as leads in future.
Export Options
About this article
Cite this article as:
Das Sucharita, Chakraborty Sandipan and Basu Soumalee, Fragment-based Designing for the Generation of Novel Leads Against BACE1, Central Nervous System Agents in Medicinal Chemistry 2015; 15 (1) . https://dx.doi.org/10.2174/1871524915666150127122546
DOI https://dx.doi.org/10.2174/1871524915666150127122546 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Nature and Nurture: Genetic Influences and Gene-Environment Interactions in Depression
Current Psychiatry Reviews An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Urine Comprehensive Drug Screen, Low Birth Weight and Withdrawal Symptoms in a Neonatal Unit: A Case Control Study
Current Clinical Pharmacology Insights into the Metal-catalyzed Alkyne Hydroarylation Reactions and Related Processes for the Synthesis of Coumarins
Current Organic Chemistry Biochemical Micro-Techniques in the Diagnosis and Classification of Amyloidosis
Current Pharmaceutical Analysis Meet Our Editorial Board Member:
Current Psychiatry Reviews Synthesis and Anticonvulsant Effect of Novel Thiazolidinedione Containing Benzene-sulfonylurea and Sulfonylthiourea Derivatives
Central Nervous System Agents in Medicinal Chemistry Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease
Mini-Reviews in Medicinal Chemistry Study of the Relationships between COVID-19, Associated Diseases, and Vitamins
Coronaviruses Safflor Protected Rat Cerebral Ischemia-Reperfusion Injury Through Inhibiting the Expression of NF-kB and IL-1β
Neuroscience and Biomedical Engineering (Discontinued) Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT<sub>1A</sub> Receptors as New Antipsychotical or Anti-Parkinsonian Agents
Current Medicinal Chemistry Preface
Current Neuropharmacology